CONSUMER NEWS    RECALLS    COMPLAINT FORM    SCAM ALERTS  


Complain about a product or service

Small Claims Guide | Class Actions | Lemon Law | FAQ | Resources | Newsletters | Spanish
Automotive    Education    Electronics    Family    Finance    Health    Homeowners    Shopping    Travel   
NEWS   Latest |  Archives |  Auto |  Cells, etc. |  Computers |  Financial |  Health |  Homeowners |  Parents |  Privacy |  Scams |  Seniors |  Travel

Trials Show Herceptin Aids Breast Cancer Recovery





April 26, 2005

Breast Cancer

What Women -- and Men -- Should Know about Breast Cancer
Daily Aspirin May Reduce Risk of Breast Cancer
FDA Approves New Genetic Test for Breast Cancer
Gene Mutation Spreads Breast Cancer
Research Finds Green Tea Helpful Against Breast Cancer
Marijuana Compound May Fight Breast Cancer
Mayo Clinic Sees New Hope In Breast Cancer Drug
FDA Approves Evista For Reducing Breast Cancer Risk
Side Effects Drive Women from Breast Cancer Drug
Hypnosis Reduces Pain and Costs in Breast Cancer Surgery
Grapefruit Linked to Breast Cancer
Study Finds No Link Between Abortion, Miscarriage and Breast Cancer
Falling Breast Cancer Rates Linked to Declining Use of Hormone Replacement Therapy
Hispanic Women Three Times More Likely to Develop Advanced Breast Cancer
MRI Screening of Opposite Breast Necessary for Women with Breast Cancer
FDA Approves Tykerb for Advanced Breast Cancer Patients
FDA Clears New Breast Cancer Test
Needle Biopsy May Not Be Enough to Rule Out Breast Cancer in Some Cases
Red Meat May Increase Breast Cancer Risk
Breast Cancer Survivors Skipping Mammograms, Study Finds
Breast Implant Complications Frequent, Study Finds
Tests Show Drug Fights Aggressive Breast Cancer
California Sues to Require Cancer Warnings on Potato Chips and French Fries
Study Ties Fries To Breast Cancer Risk
Low-Fat Diet May Reduce Risk of Recurrent Breast Cancer
Study Suggests Pain Reliever, Breast Cancer Link
Trials Show Herceptin Aids Breast Cancer Recovery
That Pink Ribbon Can Be Misleading, Consumer Group Warns
Survival Better When Breast Cancer Detected Through Mammography

The drug Herceptin has produced promising results in trials for the treatment of breast cancer. The drug, developed by Genentech, is used to treat women with the early stage of the disease, and who have undergone surgery.

The National Cancer Institute, one of the test's two sponsors, said it concluded the clinical trials early after Herceptin and chemotherapy showed such strong promise as a treatment. The patients who received Herceptin and chemotherapy had a 52 percent decrease in disease recurrence, compared with women treated only with chemotherapy.

The trials compared Herceptin plus chemotherapy to chemotherapy alone as adjuvant therapy following initial treatment with surgery for women with early-stage, or cancer that has not spread beyond the breast and associated lymph nodes, human epidermal growth factor receptor 2 (HER2) positive breast cancer.

"The data from these very important Phase III trials suggest for the first time that a therapy that targets women whose tumors have a specific genetic mutation has the potential to reduce the recurrence of disease in early-stage breast cancer patients," said Susan Desmond-Hellmann, M.D., M.P.H., Genentech's president of Product Development.

"While further follow-up is necessary, the results of this joint interim analysis suggest that adjuvant therapy with Herceptin plus chemotherapy for women with early-stage HER2-positive breast cancer may increase the chance of long-term survival."

The NCCTG study enrolled its first patient in June 2000 and has enrolled 3,406 patients to date; the NSABP study began enrollment in March 2000 and has enrolled 2,085 patients to date. The interim analysis was based on information from 3,300 patients. These studies will stop enrolling new patients and the cooperative groups will continue to monitor patients for longer-term data. Each of the studies was a randomized, controlled trial that evaluated the combination of anthracycline and cyclophosphamide (AC) followed by paclitaxel, with or without Herceptin using different treatment schedules of paclitaxel in women with HER2-positive breast cancer.

Adverse events in these studies were consistent with those seen in previous Herceptin clinical trials. Each of these studies has an independent, external Data Monitoring Committee (DMC) that reviewed data from the studies, including cardiac safety data. The DMCs monitored safety data on a regular basis and there were three to four percent more cases of serious or life-threatening (and in rare cases, fatal) cardiac events, most commonly congestive heart failure (weakening of the heart muscle) in patients receiving the combination of Herceptin plus chemotherapy. Patients in these studies will continue to be followed for any additional side effects.

Herceptin is a targeted therapeutic antibody treatment for women with HER2-positive metastatic breast cancer, an especially aggressive form of the disease that affects approximately one-fourth of women with breast cancer. Special testing is required to identify women who are HER2-positive and candidates for treatment with Herceptin.

Herceptin received U.S. Food and Drug Administration (FDA) approval in September 1998 for use in women with metastatic breast cancer who have tumors that overexpress the HER2 protein. It is indicated for weekly treatment of patients both as first-line therapy in combination with paclitaxel and as a single agent in second- and third-line therapy.

Genentech says Herceptin therapy does involve risks. Serious side effects have occurred in patients treated with Herceptin in metastatic breast cancer. Herceptin administration can result in the development of ventricular dysfunction and cardiac failure. Severe hypersensitivity reactions (including anaphylaxis), infusion reactions, and pulmonary events have been infrequently reported. Rarely, these were fatal.



Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.


Consumer News

July 9 2008

Recent Recalls & Safety Alerts

Print, mail, etc.




FREE CONSUMER NEWSLETTERS

The Daily Consumer
Afternoons M-F

Sign up now!


Consumer News & Alerts
Every Sunday

Sign up now!


Knowledge is free.
Knowledge is power.

Back to the top |

Advertisement


Home | Rogues Gallery | Good Guys | Complaint Form | News | Recalls | Search | Video | FAQ |
Consumer Resources | Small Claims Guide | Lemon Law | Newsletter | Contact Us
Advertise With Us | Testimonials | Newsroom | RSS Feeds | Radio | Job Postings




Terms of Use Your use of this site constitutes acceptance of the Terms of Use

Advertisements on this site are placed and controlled by outside advertising networks. ConsumerAffairs.com does not evaluate or endorse the products and services advertised. See the FAQ for more information.

Company Response Welcome If complaints about your company appear on our site, we welcome your response. Please see the Response Form for more information.

For more information, see the FAQ and privacy policy. The information on this Web site is general in nature and is not intended as a substitute for competent legal advice.  ConsumerAffairs.com Inc. makes no representation as to the accuracy of the information herein provided and assumes no liability for any damages or loss arising from the use thereof. 

Copyright © 2003-2008 ConsumerAffairs.com Inc.  All Rights Reserved.